A new study from the University of Chicago and Scripps Research Institute shows that during the last great pandemic—2009’s H1N1 influenza pandemic—people developed strong, effective immune responses to stable, conserved parts of the virus.
Published today in Nature Communications, the team from the Peter Doherty Institute for Infection and Immunity (Doherty Institute), Alfred Health and Monash University sought to understand which patients would recover quickly from influenza and which would become severely ill.
By engineering a short chunk of protein, or peptide, that can prevent the attachment of human parainfluenza viruses to cells, researchers have improved a method in rodent models intended to help keep children healthy.
In its latest clinical practice guideline on community-acquired pneumonia the American Thoracic Society’s guidelines panel addresses the use of nucleic acid-based testing for non-influenza viral pathogens. The guideline was published online in the May 1 issue of the American Journal of Respiratory and Critical Care Medicine. An explainer video may be viewed here.
The National Institutes of Health has awarded the University of Georgia a contract to establish the Center for Influenza Disease and Emergence Research (CIDER). The contract will provide $1 million in first-year funding and is expected to be supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, for seven years and up to approximately $92 million.
Penn Medicine has been selected as one of five sites across the country to serve as a Center of Excellence for Influenza Research and Response (CEIRR), with the goal of better understanding influenza viruses around the world along with learning about the viral strains that have the potential to cause pandemics. Penn Medicine has been awarded nearly $7 million in first-year funding.
People who received a flu shot last flu season were significantly less likely to test positive for a COVID-19 infection when the pandemic hit, according to a new study. And those who did test positive for COVID-19 had fewer complications if they received their flu shot.
The team at Beth Israel Deaconess Medical Center demonstrated that COVID-19 cases resulted in significantly more weekly hospitalizations, more use of mechanical ventilation and higher mortality rates than influenza.
Scientists at Washington University School of Medicine in St. Louis have implicated a type of immune cell in the development of chronic lung disease that sometimes is triggered following a respiratory viral infection. The evidence suggests that activation of this immune cell serves as an early switch that, when activated, drives progressive lung diseases, including asthma and chronic obstructive pulmonary disease (COPD).
A novel computer algorithm that could create a broadly reactive influenza vaccine for swine flu also offers a path toward a pan-influenza vaccine and possibly a pan-coronavirus vaccine as well, according to a new paper published in Nature Communications.
A child’s first influenza infection shapes their immunity to future airborne flu viruses – including emerging pandemic strains. But not all flu strains spur the same initial immune defense, according to new findings published today by University of Pittsburgh virologists.
As we struggle to vaccinate faster than COVID variants spread, new research from Michigan State University used health data following the initial 1918 influenza spike to provide insights to what “pandemic reemergence” will look like for our future.
A silver lining is emerging amid the COVID-19 pandemic. Influenza numbers are way down – 98 percent down, according to the CDC. Locally, during flu season last year, Houston Methodist’s system of eight hospitals saw 250 to 450 flu cases per week. This year the hospital system has seen only 2 to 5 flu cases per week so far. The numbers tell a striking story. Handwashing, masking and social distancing work.
Flu cases are down this year, mostly because all the COVID-19 precautions like hand-washing and social distancing. That doesn’t mean you shouldn’t stay vigilant. In fact, it might be more important now than ever.
Thirty-five people have died in the custody of U.S. Immigration and Customs Enforcement (ICE) since April 2018, with a seven-fold increase in deaths even as the average daily population decreased by nearly a third between 2019 and 2020, a new USC study shows.
New research by scientists at the University of Chicago suggests a person’s antibody response to influenza viruses is dramatically shaped by their pre-existing immunity, and that the quality of this response differs in individuals who are vaccinated or naturally infected. Their results highlight the importance of receiving the annual flu vaccine to induce the most protective immune response.
A vaccine that induces immune responses to a wide spectrum of influenza virus strains and subtypes has produced strong and durable results in early-stage clinical trials in humans, Mount Sinai researchers have found.
In a controlled study, scientists found that smokers and e-cigarette users exhibited significantly altered immune responses to a model of influenza virus infection, suggesting increased susceptibility to disease, including COVID-19
A new study published online in the Annals of the American Thoracic Society reveals how patients hospitalized with severe COVID-19 fared, compared to those hospitalized with severe seasonal influenza. The study is believed to be the first in the U.S. to directly compare clinical features, laboratory results and health outcomes between patients with the two diseases.
As the race for a COVID-19 vaccine intensifies, health care officials are reminding the public not to forget another important vaccine this fall: the flu shot. Flu season in the U.S. technically began in September, with illnesses expected to peak in December and February, according to the Centers for Disease Control (CDC). Less than half of Americans received a flu vaccine during the 2019-2020 flu season, and a staggering 405,000 hospitalizations and 22,000 deaths were attributed to influenza.
New research from an immunology team at the University of Chicago may shed light on the challenges of developing a universal flu vaccine that would provide long-lasting and broad protection against influenza viruses.
This year's flu season won't be like any other, due to the ongoing COVID-19 (coronavirus) pandemic. Because the flu and COVID-19 can present in similar ways, anyone who experiences overlapping symptoms of the two viruses may have to assume it's COVID-19 unless testing is performed, according to Cedars-Sinai experts.
The J. Willard Marriott Library is launching a new digital exhibit to explore the 1918 flu pandemic in Utah through contemporary newspaper articles. The articles show how the issues and divisions that have appeared in the COVID-19 pandemic are, unfortunately, nothing new.
Today, on World Lung Day (WLD), the American Thoracic Society is united with members of the Forum of International Respiratory Societies (FIRS) and WLD partner organizations to advocate for respiratory health globally and call for more research to prevent, detect and treat respiratory infections.
Researchers have identified two antibodies that protect mice against lethal infections of influenza B virus, report scientists at Washington University School of Medicine in St. Louis and Icahn School of Medicine at Mount Sinai. Together with an antibody that targets the other major kind of influenza viruses that infect people — influenza A — these antibodies potentially could form the basis of a broad-spectrum flu drug that could treat almost all flu cases.
As the COVID-19 pandemic continues with no end in sight, the annual flu season emerges once again. Cases of the flu have already begun to surface around the nation, and there are some reports of co-infection with COVID-19. Johns Hopkins Medicine experts say now is the time to take action to fight against the flu. Doctors recommend that everyone age 6 months and older get the flu vaccine each year to prevent infection from the virus or reduce the severity of the illness.
As Americans begin pulling up their sleeves for an annual flu vaccine, researchers at the University of Wisconsin–Madison have provided new insights into an alternative vaccine approach that provides broader protection against seasonal influenza.
With flu season fast approaching, health officials are urging the public to help contain the spread of influenza and avoid another outbreak amid the ongoing COVID-19 pandemic. The two viruses are very similar, and it's going to make this flu season very challenging.
As the COVID-19 pandemic continues to impact the world in sometimes devastating and unexpected ways, a more well-known illness — the flu — will make its annual debut in the coming weeks. Flu activity tends to increase in October and can run as late as May. It’s too soon to tell how flu season will definitively affect the current pandemic. However, Johns Hopkins Medicine experts say prevention will be key in reducing the spread of both illnesses, including getting an annual flu vaccine, washing hands, wearing a face mask or covering, and maintaining proper physical distancing.
Repeated exposure to influenza viruses may undermine the effectiveness of the annual flu vaccine. A team of researchers led by Washington University School of Medicine in St. Louis has developed an approach to assess whether a vaccine activates the kind of immune cells needed for long-lasting immunity against new influenza strains. The findings could aid efforts to design an improved flu vaccine.
Many viruses mutate so quickly that identifying vaccines or treatments is like trying to hit a moving target. Now, scientists report a new technique that can detect minor changes in RNA sequences. They present their results today at the American Chemical Society Fall 2020 Virtual Meeting & Expo.